CHD4 and melanoma: The ability to target Mi-2β and recover ISG expression and inflammatory signals by Z36-MP5 developed here might be further evaluated for integration of combinational immunotherapy in patients with melanoma and other immune resistant cancers in future translational and clinical researches.